Peptides for activation and inhibition of δPKC
AssigneesNational Institute of Health (NIH), The United States of America as represented by the Department of Health and Human Services, The United States of America as represented by NIH Division of Extramural Inventions and Technology Resources (DEITR)
InventorsDaria Mochly-Rosen, Leon E. Chen
Life of this patent
Estimating the term…
Abstract
Peptides able to inhibit or activate the translocation or function of δPKC are identified. Administration of the peptides for protection or enhancement of cell damage due to ischemia is described. Therapeutic methods to reduce damage to cells or to enhance damage to cells due to ischemia are also described, as well as methods for screening test compounds for δPKC-selective agonists and antagonists.
Claims11
A method for reducing cardiac tissue damage in a subject due to ischemia, comprising:
- administering to said subject a conjugate comprising (a) a peptide comprising the amino acid sequence of SEQ ID NO:
- 4, and (b) a transport moiety effective to facilitate transport across a cell membrane, wherein said peptide and transport moiety are linked, and wherein said administering is effective to reduce cardiac tissue damage due to ischemia.
A method for reducing cardiac tissue damage in a subject due to ischemia, comprising:
- administering to said subject a conjugate comprising (a) a first peptide comprising the amino acid sequence of SEQ ID NO:
- 4, and (b) a second peptide comprising the amino acid sequence of SEQ ID NO:
- 9, wherein said first and second peptides are cross-linked via a disulfide bond, and wherein said administering is effective to reduce cardiac tissue damage due to ischemia.
A method for reducing cardiac tissue damage in a subject due to ischemia, comprising:
- administering to said subject a conjugate comprising (a) a first peptide consisting of the amino acid sequence of SEQ ID NO:
- 4 and a first terminal cysteine, and (b) a second peptide consisting of the amino acid sequence of SEQ ID NO:
- 9 and a second terminal cysteine, wherein the first and second peptides are cross-linked via a disulfide bond between the first and second terminal cysteine, and wherein said administering is effective to reduce cardiac tissue damage due to ischemia.
A method for reducing cardiac tissue damage in a subject due to ischemia, comprising:
- administering to said subject a composition comprising a conjugate and a carrier or encapsulant, wherein said conjugate comprises (a) a peptide comprising the amino acid sequence of SEQ ID NO:
- 4, and (b) a transport moiety effective to facilitate transport across a cell membrane, wherein said peptide and transport moiety are linked, and wherein said administering is effective to reduce cardiac tissue damage due to ischemia.
A method for reducing cardiac tissue damage in a subject due to ischemia, comprising:
- administering to said subject a composition comprising a conjugate and a carrier or encapsulant, wherein said conjugate comprises (a) a first peptide comprising the amino acid sequence of SEQ ID NO:
- 4, and (b) a second peptide comprising the amino acid sequence of SEQ ID NO:
- 9, wherein the first and second peptides are cross-linked via a disulfide bond, and wherein said administering is effective to reduce cardiac tissue damage due to ischemia.
A method for reducing cardiac tissue damage in a subject due to ischemia, comprising:
- administering to said subject a composition comprising a conjugate and a carrier or encapsulant, wherein said conjugate comprises (a) a first peptide consisting of the amino acid sequence of SEQ ID NO:
- 4 and a first terminal cysteine;
- and (b) a second peptide consisting of the amino acid sequence of SEQ ID NO:
- 9 and a second terminal cysteine, wherein the first and second peptides are cross-linked via a disulfide bond between the first and second terminal cysteine, and wherein said administering is effective to reduce cardiac tissue damage due to ischemia.
Dependencies are inferred from the claim text.